NGGN Melanoma Practice Guidelines

ONCOLOGY

Volumn 12, Issue 7 A, 1998, Pages 153-177

  Houghton, Alan ^a   Coit, Daniel ^a   Bloomer, William ^b   Buzaid, Antonio ^c   Chu, David ^d   Eisenberg, Burton ^e   Guitart, John ^f   Johnson, Timothy ^g   Miller, Stanley ^h   Sener, Steven ^b   Tanabe, Kenneth ⁱ   Thompson, John ^j   Urist, Marshall ^k   Walker, Michael ^l  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EVANSTON HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CLINICAL PROTOCOL; CONFERENCE PAPER; MELANOMA; PRACTICE GUIDELINE; TREATMENT PLANNING;

HUMANS; MELANOMA;

EID: 0031828737     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997.
2. Fleming ID, Cooper JS, Henson DE, et al (eds): AJCC Cancer Staging Manual, 5th ed, pp 163-167. Philadelphia, Lippincott-Raven, 1997.
3. After treatment of early melanoma, should patients and family members be followed? Why and how? NIH Consens Statement 10(1): 1-26, 1992.
4. Buzaid AC, Sandler AB, Mani S, et al: Role of computed tomography in the staging of primary melanoma. J Clin Oncol 11 (4):638-643, 1993
5. Kuvshinoff BW, Kunz C, Coit DG : Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 4(3):252-258, 1997.
6. Johnson TM, Fader DJ, Chang AE, et al: Computed tomography in staging patients with melanoma metastatic to regional nodes. Ann Surg Oncol 4(5):396-402, 1997.
7. Veronesi U, Cascinelli N: Narrow excision (1-cm margin): A safe procedure for thin cutaneous melanoma. Arch Surg 126:438-441, 1991.
8. Balch CM, Urist MM, Karakousis CP, et al: Efficacy of 2-cm surgical margins for intermediate thickness melanomas (1 to 4 mm) - results of a multi-institutional randomized surgical trial. Ann Surg 218(3):262-269, 1993.
9. Balch CM, Soong SJ, Bartolucci AA, et al: Efficacy of elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224(3):255-266, 1996.
10. Sim FH, Taylor WF, Pritchard DJ, et al: Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study. Mayo Clin Proc 61:697-705, 1986.
11. Veronesi U, Cascinelli N, Adamus J, et al Thin stage I primary cutaneous malignant melanoma: Comparison of excision with margins of 1 or 3 cm. N Engl J Med 318:1159-1162, 1988 [published erratum appears in N Engl J Med 25;325(4):292, 1991].
12. Coit DG, Brennan MF: Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 124:162-166, 1989.
13. Bauer R, Kopald K, Lee J, et al: Long-term results of intralesional BCG for locally-advanced recurrent melanoma. Proc Am Soc Clin Oncol 9:276, 1990.
14. Waters RA, Clement RM, Thomas JM: Carbon dioxide laser ablation of cutaneous me- tastases from malignant melanoma. Br J Surg 78:493-494, 1991.
15. Fraker DL, Coit DG: Isolated perfusion of extremity tumors, in Lotze MT, Rubin JT (eds): Regional Therapy of Advanced Cancer, pp 333-350. Philadelphia, Lippincott-Raven, 1997.
16. Kirkwood JM, Strawderman MH, Emstoff MS, et al: Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST-1684. J Clin Oncol 14:7-17, 1996.
17. Strom EA, Ross MI: Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: Toxicity and local control Ann Surg Oncol 2(5)-445-449, 1995.
18. Jillela A, Mani S, Nair B, et al: The role of close follow-up of melanoma patients with AJCC stages I-III: A preliminary analysis. Proc Am Soc Clin Oncol 14:413, 1995.
19. Basseres N, Grob JJ, Richard MA, et al: Cost-effectiveness of surveillance of stage I melanoma. Dermatology 191:199-203, 1995.
20. Kang S, Barnhill R, Mihm MC, et al: Multiple primary cutaneous melanoma. Cancer 70.1911-1916, 1992.
21. Fawzy FI, Fawzy NW, Hyun CS, et al: Malignant melanoma: Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 50:681-689, 1993.
22. Rigel DS, Rivers JK, Kopf AW, et al: Dysplastic nevi - markers for increased risk for melanoma. Cancer 63-386-389, 1989.
23. Gutman M, Cnaan A, Inbar M, et al: Are malignant melanoma patients at higher risk for a second cancer? Cancer 68:660-665, 1991.
24. Weiss M, Loprinzi CL, Greagan ET, et al: Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma JAMA 274(21): 1703-1705, 1995.